284 related articles for article (PubMed ID: 22554716)
1. A randomized controlled crossover trial with delayed-release cysteamine bitartrate in nephropathic cystinosis: effectiveness on white blood cell cystine levels and comparison of safety.
Langman CB; Greenbaum LA; Sarwal M; Grimm P; Niaudet P; Deschênes G; Cornelissen E; Morin D; Cochat P; Matossian D; Gaillard S; Bagger MJ; Rioux P
Clin J Am Soc Nephrol; 2012 Jul; 7(7):1112-20. PubMed ID: 22554716
[TBL] [Abstract][Full Text] [Related]
2. Halitosis in cystinosis patients after administration of immediate-release cysteamine bitartrate compared to delayed-release cysteamine bitartrate.
Besouw M; Tangerman A; Cornelissen E; Rioux P; Levtchenko E
Mol Genet Metab; 2012 Sep; 107(1-2):234-6. PubMed ID: 22832073
[TBL] [Abstract][Full Text] [Related]
3. Long-term treatment of cystinosis in children with twice-daily cysteamine.
Dohil R; Gangoiti JA; Cabrera BL; Fidler M; Schneider JA; Barshop BA
J Pediatr; 2010 May; 156(5):823-7. PubMed ID: 20138296
[TBL] [Abstract][Full Text] [Related]
4. Twice-daily cysteamine bitartrate therapy for children with cystinosis.
Dohil R; Fidler M; Gangoiti JA; Kaskel F; Schneider JA; Barshop BA
J Pediatr; 2010 Jan; 156(1):71-75.e1-3. PubMed ID: 19775699
[TBL] [Abstract][Full Text] [Related]
5. A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis.
van Stein C; Klank S; Grüneberg M; Ottolenghi C; Grebe J; Reunert J; Harms E; Marquardt T
Orphanet J Rare Dis; 2021 Sep; 16(1):387. PubMed ID: 34521447
[TBL] [Abstract][Full Text] [Related]
6. A novel sustained-release cysteamine bitartrate formulation for the treatment of cystinosis: Pharmacokinetics and safety in healthy male volunteers.
Berends CL; Pagan L; van Esdonk MJ; Klarenbeek NB; Bergmann KR; Moerland M; van der Wel V; de Visser SJ; Büller H; de Loos F; de Vries WS; Waals H; de Leede LGJ; Burggraaf J; Kamerling IMC
Pharmacol Res Perspect; 2021 Apr; 9(2):e00739. PubMed ID: 33764642
[TBL] [Abstract][Full Text] [Related]
7. Treatment of cystinosis with delayed-release cysteamine: 6-year follow-up.
Dohil R; Cabrera BL
Pediatr Nephrol; 2013 Mar; 28(3):507-10. PubMed ID: 23001048
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients.
Bouazza N; Tréluyer JM; Ottolenghi C; Urien S; Deschenes G; Ricquier D; Niaudet P; Chadefaux-Vekemans B
Orphanet J Rare Dis; 2011 Dec; 6():86. PubMed ID: 22195601
[TBL] [Abstract][Full Text] [Related]
9. Switching from immediate- to extended-release cysteamine in nephropathic cystinosis patients: a retrospective real-life single-center study.
Ahlenstiel-Grunow T; Kanzelmeyer NK; Froede K; Kreuzer M; Drube J; Lerch C; Pape L
Pediatr Nephrol; 2017 Jan; 32(1):91-97. PubMed ID: 27350621
[TBL] [Abstract][Full Text] [Related]
10. A systematic literature review of cysteamine bitartrate in the treatment of nephropathic cystinosis.
Medic G; van der Weijden M; Karabis A; Hemels M
Curr Med Res Opin; 2017 Nov; 33(11):2065-2076. PubMed ID: 28692321
[TBL] [Abstract][Full Text] [Related]
11. Quality of life is improved and kidney function preserved in patients with nephropathic cystinosis treated for 2 years with delayed-release cysteamine bitartrate.
Langman CB; Greenbaum LA; Grimm P; Sarwal M; Niaudet P; Deschenes G; Cornelissen EA; Morin D; Cochat P; Elenberg E; Hanna C; Gaillard S; Bagger MJ; Rioux P
J Pediatr; 2014 Sep; 165(3):528-33.e1. PubMed ID: 24948347
[TBL] [Abstract][Full Text] [Related]
12. Long-term clinical benefits of delayed-release cysteamine bitartrate capsules in patients with nephropathic cystinosis (response to "A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis").
Langman CB
Orphanet J Rare Dis; 2023 Jun; 18(1):162. PubMed ID: 37353838
[TBL] [Abstract][Full Text] [Related]
13. Understanding intestinal cysteamine bitartrate absorption.
Dohil R; Fidler M; Barshop BA; Gangoiti J; Deutsch R; Martin M; Schneider JA
J Pediatr; 2006 Jun; 148(6):764-9. PubMed ID: 16769383
[TBL] [Abstract][Full Text] [Related]
14. Steady-state pharmacokinetics and pharmacodynamics of cysteamine bitartrate in paediatric nephropathic cystinosis patients.
Belldina EB; Huang MY; Schneider JA; Brundage RC; Tracy TS
Br J Clin Pharmacol; 2003 Nov; 56(5):520-5. PubMed ID: 14651726
[TBL] [Abstract][Full Text] [Related]
15. A Phase 1 Pharmacokinetic Study of Cysteamine Bitartrate Delayed-Release Capsules Following Oral Administration with Orange Juice, Water, or Omeprazole in Cystinosis.
Armas D; Holt RJ; Confer NF; Checani GC; Obaidi M; Xie Y; Brannagan M
Adv Ther; 2018 Feb; 35(2):199-209. PubMed ID: 29411268
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of enteric-coated cysteamine bitartrate in healthy adults: a pilot study.
Gangoiti JA; Fidler M; Cabrera BL; Schneider JA; Barshop BA; Dohil R
Br J Clin Pharmacol; 2010 Sep; 70(3):376-82. PubMed ID: 20716238
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in the treatment of cystinosis.
Schneider JA; Clark KF; Greene AA; Reisch JS; Markello TC; Gahl WA; Thoene JG; Noonan PK; Berry KA
J Inherit Metab Dis; 1995; 18(4):387-97. PubMed ID: 7494398
[TBL] [Abstract][Full Text] [Related]
18. Enteric-Coated Cysteamine Bitartrate in Cystinosis Patients.
Klank S; van Stein C; Grüneberg M; Ottolenghi C; Rauwolf KK; Grebe J; Reunert J; Harms E; Marquardt T
Pharmaceutics; 2023 Jun; 15(7):. PubMed ID: 37514038
[TBL] [Abstract][Full Text] [Related]
19. Suppository formulations as a potential treatment for nephropathic cystinosis.
Buchan B; Kay G; Matthews KH; Cairns D
J Pharm Sci; 2012 Oct; 101(10):3729-38. PubMed ID: 22778070
[TBL] [Abstract][Full Text] [Related]
20. A new gel formulation of topical cysteamine for the treatment of corneal cystine crystals in cystinosis: the Cystadrops OCT-1 study.
Labbé A; Baudouin C; Deschênes G; Loirat C; Charbit M; Guest G; Niaudet P
Mol Genet Metab; 2014 Mar; 111(3):314-320. PubMed ID: 24440466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
